WO1995011673A1 - Composes et procedes de traitement de la drepanocytose - Google Patents

Composes et procedes de traitement de la drepanocytose Download PDF

Info

Publication number
WO1995011673A1
WO1995011673A1 PCT/US1994/006558 US9406558W WO9511673A1 WO 1995011673 A1 WO1995011673 A1 WO 1995011673A1 US 9406558 W US9406558 W US 9406558W WO 9511673 A1 WO9511673 A1 WO 9511673A1
Authority
WO
WIPO (PCT)
Prior art keywords
pantetheine
pantethine
hydrogen
liq
patient
Prior art date
Application number
PCT/US1994/006558
Other languages
English (en)
Inventor
George M. Thurston
George B. Benedek
John I. Clark
Ghanshyam Patil
William L. Matier
Original Assignee
Oculon Corporation
Massachusetts Institute Of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oculon Corporation, Massachusetts Institute Of Technology filed Critical Oculon Corporation
Priority to AU71046/94A priority Critical patent/AU7104694A/en
Publication of WO1995011673A1 publication Critical patent/WO1995011673A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom

Definitions

  • cyclic acetals or ketals are achieved when X and Y taken together are represented by structure 7
  • cyclic orthoesters are produced when X and Y taken together are selected from structures 8, 9 or 10.
  • Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions.
  • Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like.
  • the formulations may also contain minor amounts of nontoxic auxiliary substances, such as wetting or emulsifying agents, pH buffering agents, and the like, such as, for example, sodium acetate, sorbitan monolaurate, triethanolamine oleate, and the like.
  • the derivatives of the present invention may also be pantetheine or pantethine cyclic carbonates.
  • the carbon bridge is a single carbonyl group as illustrated in structure 13.
  • Such cyclic carbonates may be prepared by treating pantetheine or pantethine with phosgene or its synthetic equivalent.
  • pantothenic acid may be treated with a ketal of acetone such as 2,2-dimethoxypropane (acetone dimethyl ketal) under acidic reaction conditions, to provide the acetone ketal of pantothenic acid by a process referred to as trans-ketalization.
  • the acetone ketal is exchanged or transferred from the ketalizing reagent, 2,2-dimethoxypropane, to pantothenic acid.
  • a solution of sodium pantothenate in acetone may be treated with a single molar equivalent of sulfuric acid followed by treatment with 2,2-dimethoxypropane.
  • Figures 5A and 5B presents the results of HPLC analysis of control samples and of serum, demonstrating conversion of S-pivaloyl pantetheine to pantetheine in serum.
  • Figure 5A illustrates the elution of pantetheine after incubation of serum with S-pivaloyl pantetheine as described above.
  • Figure 5B shows a corresponding sample of serum which was incubated without S-pivaloyl pantetheine, and no pantetheine was detected.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des composés et des procédés de traitement de la drépanocytose par prévention ou inhibition de l'intensité et/ou de la fréquence des crises, y compris de la douleur ou de complications associées, liées à cette maladie. L'invention concerne également des composés et des procédés d'inhibition de la falsiformation des érythrocytes chez un patient. Les procédés de cette invention consistent à administrer une dose efficace de pantéthine, de pantéthéine ou bien un dérivé de celle-ci à un patient, par exemple par voie parentérale ou orale.
PCT/US1994/006558 1993-10-27 1994-06-10 Composes et procedes de traitement de la drepanocytose WO1995011673A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU71046/94A AU7104694A (en) 1993-10-27 1994-06-10 Compounds and methods for treating sickle cell anemia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14423993A 1993-10-27 1993-10-27

Publications (1)

Publication Number Publication Date
WO1995011673A1 true WO1995011673A1 (fr) 1995-05-04

Family

ID=22507701

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/006558 WO1995011673A1 (fr) 1993-10-27 1994-06-10 Composes et procedes de traitement de la drepanocytose

Country Status (2)

Country Link
AU (1) AU7104694A (fr)
WO (1) WO1995011673A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015106240A1 (fr) * 2014-01-13 2015-07-16 The General Hospital Corporation Composés hétéroaryle-disulfure utilisés comme effecteurs allostériques pour augmenter l'affinité de fixation d'oxygène de l'hémoglobine
WO2014106804A3 (fr) * 2013-01-04 2017-04-13 Cellixbio Private Limited Compositions et procédés de traitement du syndrome métabolique et du diabète
US10376453B1 (en) 2016-12-29 2019-08-13 Korea Institute Of Ocean Science And Technology Composition for promoting hair growth containing novel pantetheine derivative
JP2022511469A (ja) * 2018-11-30 2022-01-31 コメット セラピューティクス インコーポレイテッド 環状パンテテイン誘導体及びその使用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
29.09.81: "NON-ENZYMATIC ACETYLATION OF HUMAN HEMOGLOBINS", BIOCHIM.BIOPHYS.ACTA, no. 670, 1902, pages 190 - 194 *
J. DEB. BUTLER ET AL.: "Pantethine depletes cystinotic fibroblasts of cystine", J.PEDIATR., vol. 102, no. 5, May 1983 (1983-05-01), pages 796 - 798 *
M.SAMPIETRO ET AL.: "USO DI UN' ASSOCIAZIONE FAMACOLOGICA CONTENENTE CARNITINA, PANTETINA, CALCIO E VITAMINE NELLA BETA-TALASSEMIA ETEROZIGOTE SINTOMATICO", ARCH.MED.INTERNA, vol. 36, no. 6, 1984, pages 329 - 336 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014106804A3 (fr) * 2013-01-04 2017-04-13 Cellixbio Private Limited Compositions et procédés de traitement du syndrome métabolique et du diabète
WO2015106240A1 (fr) * 2014-01-13 2015-07-16 The General Hospital Corporation Composés hétéroaryle-disulfure utilisés comme effecteurs allostériques pour augmenter l'affinité de fixation d'oxygène de l'hémoglobine
US10758569B2 (en) 2014-01-13 2020-09-01 The General Hospital Corporation Heteroaryl disulfide compounds as allosteric effectors for increasing the oxygen-binding affinity of hemoglobin
US10376453B1 (en) 2016-12-29 2019-08-13 Korea Institute Of Ocean Science And Technology Composition for promoting hair growth containing novel pantetheine derivative
JP2022511469A (ja) * 2018-11-30 2022-01-31 コメット セラピューティクス インコーポレイテッド 環状パンテテイン誘導体及びその使用
US12037354B2 (en) 2018-11-30 2024-07-16 Vectivbio Comet Ag Cyclic pantetheine derivatives and uses thereof

Also Published As

Publication number Publication date
AU7104694A (en) 1995-05-22

Similar Documents

Publication Publication Date Title
EP0605622A1 (fr) Derives a substitution oxygene de produits d'addition de nucleophile-oxyde nitrique utilises comme promedicaments donneurs d'oxyde nitrique
US20070066575A1 (en) Methods and compositions for mitigating pain
CN109476625A (zh) 用于制备大麻素前药的方法、药物制剂及其用途
EP0532466A2 (fr) Dérivés d'acide 5-amino-4-hydroxy-hexanoique et leur application comme agents thérapeutiques
EP1601644B1 (fr) Precurseurs de diaryl-2-(5h)-furanones liberateurs d'oxyde nitrique utilises comme inhibiteurs de la cyclooxygenase-2
IE57665B1 (en) Novel nitroxyl compounds,process for their preparation,a diagnostic media containing same
EP0312858A1 (fr) Dérivés hétérocycliques, leur préparation et agents radio sensitifs et agents antiviraux les contenant
JP4035759B2 (ja) アミノアルコールリン酸化合物、製造方法、及びその利用方法
FR2532648A1 (fr) Derives de carbostyrile, leur procede de preparation et leur application en therapeutique
CA2521589C (fr) Composes pour le traitement de troubles metaboliques
US20080227758A1 (en) Nitric Oxide Releasing Prodrugs of Diaryl-2-(5h)-Furanones as Cyclooxygenase-2 Inhibitors
WO1996026948A1 (fr) Derives phosphates d'urees et de thiourees bisubstituees
JPH09511222A (ja) ２．６−ジアルキル−４−シリルフェノール類による血清コレステロール水準の低下法
US6274747B1 (en) Polyunsaturated fatty acid derivatives and their use
WO1995011673A1 (fr) Composes et procedes de traitement de la drepanocytose
KR100266834B1 (ko) 프로스타글란딘 유도체
EP0947503B1 (fr) Dérivés de l'acide 6,8-dimercaptooctanoique substitués en 6-S et/ou 8-S par le radical (3-methylthiopropanoyl) et compositions pharmaceutiques destinées au traitement de tumeurs cancéreuses
US20230338311A1 (en) Suppression of inflammasome activation
JP2795421B2 (ja) Ｎ−アシルジペプチド、その製造方法及びそれを含有する製薬組成物
US5061711A (en) Method of curing liver diseases by using pyrrolo quinoline quinone triesters and novel pyrrolo quinoline quinone triesters
US5089492A (en) Pharmaceuticals and dietetics containing acylamino acid derivatives
EP1325904A1 (fr) Nouveaux composes aliphatiques, procede de preparation et utilisation associes
US4946963A (en) Compounds for the control of hyperlipidemia using N-substituted isoxazolidine-3,5-diones
CA2190468A1 (fr) Synthese d'acides 4-alcenyl- ou 4-alcanyl-hydroxytetroniques optiquement purs
IE57930B1 (en) Water-soluble rifampicin derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BB BG BR BY CA CN CZ FI GE HU JP KE KG KP KR KZ LK LV MD MG MN MW NO NZ PL RO RU SD SI SK TJ TT UA UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

WPC Withdrawal of priority claims after completion of the technical preparations for international publication

Free format text: US

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA